FDA plans new board to monitor drug safety, inform consumers

02/16/2005 | Washington Post, The · NYTimes.com

The move comes on the heels of congressional criticism of the FDA's oversight of drug safety and arrives on the eve of public hearings by an agency advisory panel to review concerns associated with Celebrex, Bextra and Vioxx. Michael Leavitt, secretary of the U.S. Department of Health and Human Services, said the new advisory board is "a response to a widely held concern both inside and outside Congress." The board would not have authority to withdraw drugs from the market but would advise the agency and post information for consumers on a Web site. Critics argue the new board as proposed does not go far enough, is made up of federal officials and is not an independent body. A longtime proponent of an independent review board, Dr. Alastair Wood of Vanderbilt University, asserted, "It's a huge opportunity that's been lost to introduce transparency and restore confidence in the system."

View Full Article in:

Washington Post, The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA